Treatment of central nervous system inflammation with inhibitors of basement membrane degradation

Immunology and Cell Biology

Volumn 76, Issue 1, 1998, Pages 104-113

  Parish, Christopher R ^a   Hindmarsh, Elizabeth J ^a   Bartlett, Mark R ^a   Staykova, Maria A ^b   Cowden, William B ^a   Willenborg, David O ^b  

^a Biology and Environment   (Australia)

^b CANBERRA HOSPITAL   (Australia)

Author keywords

Basement membrane; Castanospermine; Experimental autoimmune encephalomyelitis; Heparanase; Mannose phosphate receptors; Multiple sclerosis; Phosphosugars; Sulfated oligosaccharides; Sulfated polysaccharides

Indexed keywords

CASTANOSPERMINE; HEPARANASE;

ANTIINFLAMMATORY ACTIVITY; ARTICLE; BASEMENT MEMBRANE; HUMAN; IMMUNOREGULATION; LEUKOCYTE MIGRATION; MULTIPLE SCLEROSIS; NERVOUS SYSTEM INFLAMMATION; T LYMPHOCYTE ACTIVATION;

ANIMALS; ANTI-INFLAMMATORY AGENTS; AUTOANTIGENS; BASEMENT MEMBRANE; CELL MOVEMENT; CENTRAL NERVOUS SYSTEM DISEASES; HUMANS; INFLAMMATION; LEUKOCYTES; T-LYMPHOCYTES;

EID: 0031925294     PISSN: 08189641     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1440-1711.1998.00722.x     Document Type: Article

References (66)

1. Waksman BH. Multiple sclerosis. Curr. Opin. Immunol. 1989; 1: 733-9.
2. Poser CM. The pathogenesis of multiple sclerosis. J. Neurol. Sci. 1993; 115 (Suppl.): S3-15.
3. Lassmann H, Suchanek G. Ozawa K. Histopathology and the blood-cerebrospinal fluid barrier in multiple sclerosis. Ann. Neurol. 1994; 36 (Suppl.): S42-6.
4. Raine CS, The Dale E. McFarlin memorial lecture: The immunology of the multiple sclerosis lesion. Ann. Neurol. 1994; 36 (Suppl.); S61-72.
5. Raine CS. The Norton Lecture: A review of the oligodendrocyte in the multiple sclerosis lesion. J. Neuroimmunol. 1997; 77: 135-52.
6. Ewing C, Bernard CA. Insights into the etiology and pathogenesis of muliple sclerosis. Immunol. Cell Biol. 1998; 76: 47-54.
7. Bashir K, Whilaker JN. Current immunotherapy in multiple sclerosis. Immunol. Cell Biol. 1998; 76: 55-64.
8. Ruuls SR, Sedgwick JD. Cytokine-directed therapies in multiple sclerosis and experimental autoimmune encephalomyelitis. Immunol. Cell Biol. 1998; 76: 65-73.
9. Springer TA. Traffic signals on endothelium for lymphocyte recirculation and leukocyte emigration. Annu. Rev. Physiol. 1995; 57: 827-72.
10. Dianzani U, Malavasi F. Lymphocyte adhesion to endothelium. Crit. Rev. Immunol. 1995; 15: 167-200.
11. Mantovani A, Bussolino F, Introna M. Cytokine regulation of endothelial cell function: From molecular level to the bedside. Immunol. Today 1997; 18: 231-40.
12. Yurchenco PD, Schittny JC. Molecular architecture of basement membrane. FASEB J. 1990; 4: 1577-90.
13. Ratner S. Lymphocyte migration through extracellular matrix. Invasion Metastasis 1992; 12: 82-100.
14. Karakiulakis G. Degradation of intact basement membranes by human and tumour enzymes. Biochim. Biophys. Acta 1988; 967: 163-75.
15. Bar-Ner M, Mayer M, Schirrmacher V, Vlodavsky I. Involvement of both heparanase and plasminogen activator in lymphoma cell-mediated degradation of heparan sulfate in the subendothelial extracellular matrix. J. Cell Biol. 1986; 128: 299-306.
16. Vettel U, Bar-Shavit R, Simon MM, Brunner G, Vlodavsky I, Kramer MD. Coordinate secretion and functional synergism of T cell-associated serine proteinase-1 (MSTP-1) and endoglycosidase(s) of activated T cells. Eur. J. Immunol. 1991; 21: 247-51.
17. Bartlett MR, Underwood PA, Parish CR. Comparative analysis of the ability of leucocytes, endothelial cells and platelets to degrade the subendothelial basement membrane: Evidence for cytokine dependence and detection of a novel sulfatase. Immunol. Cell Biol. 1995; 73: 113-24.
18. Paterson PY. Transfer of allergic encephalomyelitis in rats by means of lymph node cells. J. Exp. Med. 1960; 111: 119-23.
19. Panitch HS, McFarlin DE. Experimental allergic encephalomyelitis: Enhancement of cell-mediated transfer by concanavalin A. J. Immunol. 1977; 119: 1134-7.
20. Ben-Nun A, Wekerle H, Cohen IR. The rapid isolation of clonable antigen-specific T lymphocyte lines capable of mediating autoimmune encephalomyelitis. Eur. J. Immunol. 1981; 11: 195-9.
21. + T cell clones in the rat: Cloning methodology and interferon-gamma secretion. J. Immunol. Methods 1989; 121: 185-96.
22. Wekerle H, Linington C. Lassmann H, Meyerman R. Cellular immune reactivity within the CNS. Trends Neurosci. 1986; 9: 271-7.
23. Hickey WF. Migration of hematogenous cells through the blood-brain barrier and initiation of CNS inflammation. Brain Pathol. 1991; 1: 97-105.
24. Ludowyk PA, Willenborg DO, Parish CR. Selective localisation of neuro-specific T lymphocytes in the central nervous system. J. Neuroimmunol. 1992; 37: 237-50.
25. Vlodavsky I. Eldor A, Haimovitz-Friedman A et al. Expression of heparanase by platelets and circulating cells of the immune system: Possible involvement in diapedesis and extravasation. Invasion Metastasis 1992; 12: 112-27.
26. Nakajima M, Irimura T, Di Ferrante D, Di Ferrante N, Nicolson GL. Heparan sulphate degradation: Relation to tumour invasive and metastatic properties of mouse B16 melanoma sublines. Science 1983; 220: 611-13.
27. Vlodavsky I. Fuks Z, Bar-Ner M, Ariav Y. Schirrmacher V. Lymphoma cell mediated degradation of sulfated proteoglycans in the subendothelial extracellular matrix: Relation to tumour cell metastasis. Cancer Res. 1983; 43: 2704-11.
28. Naparstek Y, Cohen IR, Fuks Z, Vlodavsky I. Activated T lymphocytes produce a matrix-degrading heparan sulphate endoglycosidase. Nature 1984; 310: 241-4.
29. Coombe DR, Parish CR, Ramshaw IA, Snowden JM. Analysis of the inhibition of tumour metastasis by sulphated polysaccharides. Int. J. Cancer 1987; 39: 82-8.
30. Parish CR, Coombe DR, Jakobsen KB, Bennet FA, Underwood PA. Evidence that sulphated polysaccharides inhibit tumour metastasis by blocking tumour cell-derived heparanase. Int. J. Cancer 1987; 40: 511-18.
31. Hagmar B. Experimental tumour metastasis and blood coagulability. Acta Path. Microbiol. Scand. 1970; Suppl. 211.
32. Maat B. Extrapulmonary colony formation after intravenous injection of tumour cells into heparin-treated animals. Br. J. Cancer 1978; 3: 208-20.
33. Parish CR, Jakobsen KB, Coombe DR. The anti-metastatic activity of sulphated polysaccharides. In: Hersey P (ed.) Biological Agents in the Treatment of Cancer. Newcastle: NSW Govt. Printer, 1990; 295-302.
34. Irimura T, Nukajima M, Nicolson GL. Chemically modified heparins as inhibitors of heparan sulfate specific endo-beta-glucuronidase (heparanase) of metastatic melanoma cells. Biochemistry 1986; 25: 5322-8.
35. Chelmicka-Szone E, Arnason BGW. Partial suppression of experimental allergic encephalomyelitis with heparin. Arch. Neurol. 1972; 27: 153-8.
36. Sy MS, Schneeberger E, McCluskey R, Green MI, Rosenberg RD, Benacerraf B. Inhibition of delayed-type hypersensitivity by heparin depleted of anticoagulant activity. Cell. Immunol. 1983; 82: 23-32.
37. Willenborg DO, Parish CR. Inhibition of allergic encephalomyelitis in rats by treatment with sulfated polysaccharides. J. Immunol. 1988; 140: 3401-5.
38. Willenborg DO, Parish CR. Inhibition of passive allergic encephalomyelitis with sulfated polysaccharides. Ann. NY Acad. Sci. 1988; 540: 543-6.
39. Lider O, Baharav E, Mekori YA et al. Suppression of experimental autoimmune diseases and prolongation of allograft survival by treatment of animals with low doses of heparins. J. Clin. Invest. 1989; 83: 752-6.
40. Belford DA, Hendry IA, Parish CR. Ability of different chemically modified heparins to potentiate the biological activity of heparin-binding growth factor 1 (HBGF-1; acidic fibroblast growth factor): Lack of correlation with growth factor binding. Biochemistry 1991; 31: 6498-503.
41. Freeman C, Parish CR. A rapid quantitative assay for the detection of mammalian heparanase activity. Biochem. J. 1997; 325: 229-37.
42. Jin L, Nakajima M, Nicolson GL. Immunochemical localization of heparanase in mouse and human melanomas. Int. J. Cancer 1990; 45: 1088-95.
43. Hoogewerf AJ, Leone JW. Reardon IM et al. CXC chemokines connective tissue activating peptide-III and neutrophil activating peptide-2 are heparin heparan sulfate-degrading enzymes. J. Biol. Chem. 1995; 270: 3268-77.
44. Freeman CC, Parish CR. Human platelet heparanase: Purification, characterisation and catalytic activity. Biochem. J. 1998; (in press).
45. Chen W-T. Membrane proteases: Roles in tissue remodeling and tumour invasion. Curr. Opin. Cell Biol. 1992; 4: 802-9.
46. Novokhatny N, Medved I, Mazar A, Marcotte P, Henkin J, Ingham K. Domain structure and interactions of recombinant urokinase-type plasminogen activator. J. Biol. Chem. 1992; 267: 3878-85.
47. von Figura K, Hasilik A. Lysosomal enzymes and their receptors. Ann. Rev. Biochem. 1986; 55: 167-93.
48. Kornfeld S. Trafficking of lysosomal enzymes. FASEB J. 1987; 1: 462-8.
49. Pfeffer SR. Targeting of proteins to the lysosome. In: Compans RW (ed.) Current Topics in Microbiology and Immunology. New York: Springer-Verlag, 1991; 43-65.
50. Kornfeld S. Structure and function of the mannose 6-phosphate/insulin-like growth factor II receptors. Annu. Rev. Biochem. 1992; 61: 307-30.
51. Tong PY, Gregory W, Kornfeld S. Ligand interactions of the cation-independent mannose 6-phosphate receptor: The stoichiometry of ligand binding. J. Biol. Chem. 1989; 264: 7962-9.
52. Brauker JH, Roff CF, Wang JL. The effect of mannose 6-phosphate on the turnover of the proteoglycans in the extracellular matrix of human fibroblasts. Exp. Cell Res. 1986; 164: 115-26.
53. Willenborg DO, Parish CR. Phosphosugars are potent inhibitors of central nervous system inflammation. FASEB J. 1989; 3: 1968-71.
54. Willenborg DO, Parish CR, Cowden WB. Inhibition of adjuvant arthritis in the rat by phosphosugars and the α-glucosidase inhibitor castanospermine. Immunol. Cell Biol. 1992; 70: 369-77.
55. Bartlett MRE, Warren HS, Cowden WB, Parish CR. Effects of the anti-inflammatory compounds castanospermine, mannose-6-phosphate and fucoidan on allograft rejection and elicited peritoneal exudates. Immunol. Cell Biol. 1994; 72; 367-74.
56. Bartlett MR, Cowden WB, Parish CR. Differential effects of the anti-inflammatory compounds heparin, mannose-6-phosphate, and castanospermine on degradation of the vascular basement membrane by leukocytes, endothelial cells, and platelets. J. Leukocyte Biol. 1995; 57: 207-13.
57. Bleekmolen JE, Stein M, von Figura K, Slot JW, Geuze HJ. The two mannose 6-phosphate receptors have almost identical subcellular distributions in U937 monocytes. Eur. J. Cell Biol. 1988; 47: 366-72.
58. Hohenschutz LD, Bell EA, Jewess PJ et al. Castanospermine, a 1,6,7,8-tetrahydroxy-octahydroindolizine alkaloid from seeds of Castanospermum australe. Phytochemistry 1981; 20: 811-14.
59. Elbein AD. Inhibitors of the biosynthesis and processing of N-linked oligosaccharides. Ann. Rev. Biochem. 1987; 56: 497-534.
60. Willenborg DO, Parish CR, Cowden WB. Inhibition of experimental allergic encephalomyelitis by the alpha-glucosidase inhibitor castanospermine. J. Neurol. Sci. 1989; 90: 77-85.
61. Grochowicz PM, Hibberd AD, Bowen KM et al. Castanospermine, an α-glucosidase inhibitor, prolongs renal allograft survival in the rat. Transplant Proc. 1990; 22: 2117-18.
62. Grochowicz PM, Bowen KM, Hibberd AD, Clark DA, Cowden WB, Willenborg DO. Castanospermine, an inhibitor of glycoprotein processing, prolongs pancreaticoduodenal allograft survival. Transplant Proc. 1992; 24: 2295-6.
63. Grochowicz PM, Smart YC, Bowen KM et al. Interference with intracellular carbohydrate processing by castanospermine prolongs heart allograft survival. Transplant Proc. 1993; 25: 743-5.
64. Grochowicz PM, Hibberd AD, Bowen KM et al. Synergism of castanospermine and FK 506. Transplant Proc. 1995; 27: 355-6.
65. Parish C, Willenborg D, Cowden W. Novel inhibitors of inflammation. Today's Life Sci. 1990; 2: 20-7.
66. Karlsson GB, Butters TD, Dwek RA, Platt FM. Effects of the imino sugar N-butyldeoxynojirimycin on the N-glycosylation of recombinant gp120. J. Biol. Chem. 1993; 268: 570-6.